Overview
OCUMENSION-B (1477)
Ocumension Therapeutics, together with its subsidiaries, engages in the research, discovery, development, and commercialization of ophthalmic therapies in China...
- Open
- 5.195
- High
- 5.200
- Low
- 4.665
- Prev. Close
- 4.975
- Volume
- 395.50K
- Turnover
- 1.94M
- Avg Price
- 4.914
- Bid/Ask Ratio
- -42.86%
- Amplitude
- 10.75%
- 52wk High
- 8.780
- Volume Ratio
- 0.20
- Turnover Ratio
- 0.05%
- 52wk Low
- 4.040
- HK Mkt Cap
- 3.85B
- Market CapHKD
- 3.85B
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -0.177
- EPSDynamic
- -0.280
- EPSStatic
- --
- BVPS
- 5.12
- P/B
- 0.92
- HK Shares
- 815.38M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 815.38M
- Min lot size
- 500
- Currency
- HKD
OCUMENSION-B Analyst Rating
View moreForecast & Rating
Sep 1, 2026- Strong buy50.00%
- Buy0.00%
- Hold50.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 1
- Buy
- 0
- Hold
- 1
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 16
Ocumension Therapeutics declined 4.95% to HKD 4.725 today, pressured by sector headwinds and broad biotech financing concerns. The stock staged an intraday surge to HKD 5.200 in morning trading but reversed sharply to close near session lows at HKD 4.725, reflecting profit-taking after recent volatility. On fundamentals, Q2 FY26 revenue climbed 51.9% year-over-year to HKD 244.7 million, with net losses improving 21.12% to HKD -57.2 million, suggesting operational leverage is beginning to emerge. The pipeline continues to progress, with OT-101 for myopia hitting its Phase III primary endpoint in China and multiple eye-care candidates completing regulatory submissions or enrollment milestones. However, the company remains loss-making with a -23.37% net profit margin; the stock has fallen 37.42% year-to-date and 47.15% from its 52-week high of HKD 8.94, placing it in an extended downtrend. Goldman Sachs maintains a Hold rating on the name, underscoring market skepticism around timing to profitability and near-term recovery prospects.
- Nov, 13
Ocumension Therapeutics declined sharply today as profit-taking pressured the stock, falling from an opening of HK$5.28 to a close of HK$4.975, a decline of nearly 6%. The stock had surged to intraday high of HK$5.30 in morning trading but surrendered gains in afternoon sessions. Fundamentally, H1 revenue grew 44.1% year-over-year to HK$244.7M, reflecting solid commercial momentum; however, the company remains unprofitable with a net margin of -23.37%, highlighting persistent earnings headwinds. On the pipeline, recent highlights include NMPA acceptance for the OT-301 glaucoma therapy and OT-502 dexamethasone implant, while Phase III trials of OT-101 for myopia progressed smoothly; nonetheless, commercialization timelines remain lengthy. From a valuation perspective, the stock has fallen 34.11% year-to-date and declined 44.35% from its 52-week high of HK$8.94, now trading near the 52-week low of HK$4.04. While the long-term pipeline shows promise, near-term profitability challenges persist.
- Nov, 12
Ocumension rose marginally by 0.4% to 4.975 HKD today, as morning strength at 5.050 gave way to afternoon consolidation, resulting in 6.2% intraday range. Recent clinical progress provides support for the stock, including myopia candidate OT-101 achieving its primary efficacy endpoint in China Phase III trials and glaucoma drug OT-301 receiving NMPA filing acceptance. H1 FY2026 revenue reached RMB 423.7 million, up 44.1% year-over-year, with net losses narrowing to RMB 99.02 million. Despite strong revenue growth, the company remains unprofitable with a net margin of -23.37%. On valuation metrics, the stock has declined 34.11% year-to-date and trades 44.35% below its 52-week high of 8.94 HKD, signaling a reset from earlier peaks, though still 23.14% above the 52-week low of 4.04 HKD.
- Nov, 11
Ocumension fell from intraday peak of HK$5.265 to HK$4.955, down nearly 7%, driven primarily by profit-taking following recent gains. After OT-101 Phase III hit primary efficacy endpoint in October and OT-401 secured NMPA approval in early November, the stock surged two consecutive days (up 7% and 8% respectively), but subsequent profit-taking emerged as positive catalysts were digested. H1 revenue surged 51.9% year-over-year to HK$485.5 million, yet net loss remained at HK$113.5 million; though the loss margin narrowed 21% year-over-year, long-term profitability pathway requires validation. The stock has plunged 34.37% year-to-date and approaches its 52-week low, leaving only 22.65% upside to the low. Goldman Sachs maintained a Hold rating, reflecting institutional caution on the company's commercialization pace and profitability trajectory.
- Nov, 9
Ocumension closed at HKD 5.06 today with a modest gain of just 0.2%, after displaying divergent intraday performance—the morning session rallied to HKD 5.135 (at 09:42 BJ) but afternoon weakness brought the stock down to HKD 5.03 before a modest recovery into the close. The intraday volatility reflects profit-taking following a sequence of positive catalysts: NMPA approval for the implantable corticosteroid OT-401 and Phase III success for the myopia drug OT-101 in a China cohort have supported share prices in recent days. However, underlying fundamentals present a mixed picture—H1 revenues surged 51.9% year-on-year to HKD 244.7 million and net losses narrowed by 21.1%, yet the company remains unprofitable with a net margin of -23.4%. Viewed from a technical angle, the stock has retreated 43.4% from its 52-week high of HKD 8.94 and is down roughly 33% year-to-date, while today's turnover ratio of just 0.01% signals thin liquidity and limited market participation.
News
Market Movers · Ocumension drops 6% in Hong Kong trading
Market Movers · OCUMENSION-B rose approximately 7%
Market Movers · Ocumension falls nearly 7% in Hong Kong trading
Market Movers · OCUMENSION-B rose approximately 8%
Market Movers · Ocumension climbs 7% on NMPA approval for implant production
Tip Ranks · Ocumension Phase III Myopia Drug OT-101 Hits Primary Goal in China Cohort
